Therapeutic efficacy of artemether–lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markers
Abstract Background Plasmodium falciparum is the main cause of malaria in North-Eastern (NE) states of India. Artemether–lumefantrine (AL) was introduced as first-line therapy against uncomplicated P. falciparum cases in 2013 after the emergence of resistance to sulfadoxine–pyrimethamine. The aim of...
Saved in:
| Main Authors: | Shreelekha Dutta, Sri Krishna, Anup Kumar Vishwakarma, Sweta Mishra, Sushrikanta Khandai, Disphikha Goswami, Soni Kumari, Nazia Ali, Anil Kumar Verma, Kuldeep Singh, Aparup Das, Anup R. Anvikar, Praveen Kumar Bharti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Malaria Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12936-025-05338-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antimalarial Drug Repurposing of Epirubicin and Pelitinib in Combination with Artemether and Lumefantrine
by: Douglas O. Ochora, et al.
Published: (2025-06-01) -
Comparative in vitro dissolution profiles of marketed Artemether–Lumefantrine adult-dose tablets in Kinshasa, Democratic Republic of the Congo
by: Gloria Bujo Dhimbe, et al.
Published: (2025-06-01) -
Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients
by: Solomon M Abay, et al.
Published: (2013-06-01) -
Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
by: Bontu Abate, et al.
Published: (2025-03-01) -
A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda
by: Daniel Kabonge Kaye, et al.
Published: (2008-04-01)